-
The can rapid-risk stratification of unstable angina Patients Suppress Adverse Outcomes with Early Implementation of the ACC/AHA Guidelines (CRUSADE) is a registry study of acute coronary-syndrome patients.
-
Access-site bleeding is one of the major complications of percutaneous coronary intervention (PCI). It is associated with the need for blood transfusions, increased length of stay, and increased healthcare expenditure.
-
-
Dual-antiplatelet therapy with aspirin and clopidogrel is recommended for patients with known vascular disease or multiple risk factors for vascular disease. However, little is known about the long-term bleeding risk of such therapy.
-
Dronedarone is an antiarrhythmic drug with structural and electrophysiologic similarities to amiodarone that was released in 2009. Dronedarone's structure includes a benzofuranyl ring but, unlike amiodarone, the ring is not iodinated.
-
Little is known about the long-term prognosis of the no-reflow phenomenon after percutaneous intervention (PCI) for acute ST elevation myocardial infarction (STEMI).
-
The use of angiotensin converting enzyme (ACE) inhibitors in all acute myocardial infarction (MI) patients is controversial.
-
The optimal timing of cardiac catheterization for patients suffering non-ST segment elevation myocardial infarction (nonSTEMI) remains a subject of debate.
-
New reports about proton pump inhibitors and the effects of gastric suppression, pioglitazone vs vitamin E for non-alcoholic steatohepatitis, metformin and vitamin B12 deficiency, and FDA Actions
-